Refractory Migraine Treatment
Initial Evaluation and Treatment Approach
- The American Academy of Family Physicians recommends excluding medication overuse headaches (MOH) before escalating treatment, which occurs when acute medications are used ≥10 days/month for triptans or ≥15 days/month for NSAIDs, creating a vicious cycle where increased use of acute medications paradoxically worsens headache frequency and may lead to daily headaches 1, 2
- The American College of Physicians suggests that therapy with onabotulinumtoxinA or topiramate should be initiated immediately for refractory migraine, while optimizing acute treatment with a combination of triptan and NSAID, and strictly limiting the use of acute medications to 2 days per week to avoid MOH 1
Acute Treatment Optimization
- The American Headache Society recommends a combination of triptan and NSAID as the strongest recommendation for moderate to severe attacks, with sumatriptan 50-100 mg PLUS naproxen sodium 500 mg being a superior combination, producing 130 additional patients out of 1000 achieving sustained pain relief at 48 hours, and 90 additional patients out of 1000 achieving relief at 2 hours 1
- If a triptan fails, trying a different triptan before abandoning the class is recommended, as failure of one triptan does not predict failure of others, and ensuring the triptan is taken early in the attack while pain is still mild, as late administration reduces response rates 1, 3
Preventive Therapy
- The American Academy of Neurology recommends onabotulinumtoxinA as the only FDA-approved treatment specifically for chronic migraine prevention, with efficacy demonstrated in large randomized controlled trials, requiring 6-9 months for a complete evaluation 1
- Topiramate has demonstrated efficacy in two double-blind studies for chronic migraine prevention and is considered first-line due to its lower cost, with efficacy requiring 2-3 months for oral agents 1, 4
- Propranolol 80-240 mg/day or timolol 20-30 mg/day are first-line options with consistent evidence of efficacy 1
- Amitriptyline 30-150 mg/day is recommended for patients with mixed migraine and tension headache 1
Intravenous Treatment for Refractory Acute Attacks
- For patients requiring intravenous treatment, metoclopramide 10 mg IV has direct analgesic effects through central dopaminergic receptor antagonism, and should be considered for its efficacy and minimal risk of rebound headache 1
Avoiding Critical Pitfalls
- Never allow patients to increase the frequency of acute medication use in response to treatment failure, as this creates a vicious cycle of MOH, and instead switch to preventive therapy while optimizing acute treatment strategy 1
- Strictly limit all acute migraine medications to no more than 2 days per week to prevent MOH, with NSAIDs and triptans triggering MOH at ≥15 days/month and ≥10 days/month, respectively 1, 3
- Avoid opioids and barbiturates due to the risk of dependence, rebound headaches, and limited evidence supporting their use, and if an opioid must be used, there is better evidence for butorphanol nasal spray than for other opioids 1, 2, 4
Adjuvant Therapies
- Cognitive behavioral therapy, biofeedback, and relaxation therapy can be combined with preventive medication therapy for additional benefit, and acupuncture is a potential first-line intervention based on recent positive randomized trial results 1, 3
- Comorbid conditions such as depression, sleep disorders, obesity, and cardiovascular risk factors should be identified and treated, considering medications like amitriptyline and topiramate that treat both migraine and these conditions 4
Stepwise Approach for Treatment Failure
- A stepwise approach is recommended, starting with first-line preventives (onabotulinumtoxinA, topiramate, propranolol), escalating to second-line options if necessary, and considering anti-CGRP monoclonal antibodies for refractory cases 1